Day trading the ALDR (Alder Biopharmaceuticals Inc.) crash for an $1,150 profit.

Alder Biopharmaceuticals stock crashed nearly $6/share this morning despite positive phase 3 trials results for their eptinezumab migraine relief drug. The marginal benefit when compared to the placebo test subjects apparently brought its efficacy and commercial viability into question. After the dust settled, this unjustified crash presented a great short term bounce-buy opportunity.